Loading patent…
OwnerJulian Schofield, Thomas William Rademacher +1inventors
InventorsJulian Schofield, Thomas William Rademacher, Sylvie Deborde
Estimating the term…
The present invention relates to use of GPI-PLD antagonists for the prevention, treatment and diagnosis of pre-eclampsia. The substantial GPI-PLD activity is present in the placenta in pre-eclampsia is not expressed in the placenta, but rather is taken up from the material circulation. As a result, abnormal or dysregulated GPI-PLD activity present in the placenta in pre-eclampsia may be correctable by administration of GPI-PLD to the mother to correct the problems caused by abnormal or dysregulated GPI-PLD, e.g. to reduce the abnormal release and in situ production of placental IPGs involved in the pathogenesis of pre-eclampsia. This can be achieved using exogenous GPI-PLD or a fragment thereof, e.g. an inactive GPI-PLD capable of competing with or displacing the abnormal or dysregulated GPI-PLD, e.g. from Apo-A1.
Use of an antagonist of endogenous glycosylphosphatidylinositol phospholipase D (GPI-PLD) for the preparation of a medicament for the prevention or treatment of pre-eclampsia.
The use of any one of the preceding claims, wherein the antagonist is exogenously administered GPI-PLD.
The use of any one of the preceding claims, wherein the GPI-PLD is a fragment of full length GPI-PLD having the amino acid sequence as set out in FIG. 6.
The use of any one of the preceding claims, wherein the GPI-PLD is produced by a host cell capable of expressing and secreting GPI-PLD.
A method of diagnosing a patient who has or at risk of developing a pre-eclampsia, the method comprising determining the amount of GPI-PLD and/or GPI-PLD activity in a sample obtained from the patient.
Dependencies are inferred from the claim text.